Fig. 2From: Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover studySVR12 for all patients (ITT population) and by response to prior treatment. ITT intent-to-treat, SMV simeprevir, SVR12 sustained virologic response 12 weeks after planned end of treatmentBack to article page